{{Rsnum
|rsid=1975197
|Gene=PTPRD
|Chromosome=9
|position=8846955
|Orientation=plus
|GMAF=0.2089
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PTPRD
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 66.4 | 29.2 | 4.4
| HCB | 48.2 | 35.8 | 16.1
| JPT | 48.7 | 41.6 | 9.7
| YRI | 87.0 | 13.0 | 0.0
| ASW | 68.4 | 31.6 | 0.0
| CHB | 48.2 | 35.8 | 16.1
| CHD | 38.9 | 53.7 | 7.4
| GIH | 67.3 | 24.8 | 7.9
| LWK | 80.9 | 19.1 | 0.0
| MEX | 53.4 | 43.1 | 3.4
| MKK | 77.4 | 20.6 | 1.9
| TSI | 60.8 | 37.3 | 2.0
| HapMapRevision=28
}}
[[rs1975197]], a SNP in the motor neuron [[PTPRD]] gene, has been linked to [[restless legs syndrome]] based on a study of several European populations totaling ~2,500 patients. The odds ratio associated with the [[rs1975197]](T) risk allele is 1.31 (CI: 1.20-1.44, adjusted p = 5 x10e-9). {{PMID|18660810}}

Note that a nearby SNP, [[rs4626664]], was also shown to independently confer risk for [[restless legs syndrome]] in this same study.

{{GWAS Summary
|SNP=rs1975197
|PubMedID=18660810
|Condition=Restless legs syndrome
|Gene=PTPRD
|Risk Allele=T
|pValue=6.00E-009
|OR=1.31
|95CI=1.20-1.44
}}

{{omim
|desc=RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 3
|id=610438
|rsnum=1975197
}}

{{PharmGKB
|RSID=rs1975197
|Name_s=
|Gene_s=PTPRD
|Feature=
|Evidence=PubMed ID:18660810; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome (Initial Sample Size: 628 cases, 1,644 controls; Replication Sample Size: 1,835 cases, 3,111 controls; Risk Allele: rs1975197-T). This variant is associated with Restless legs syndrome.
|Drugs=
|Drug Classes=
|Diseases=Restless Legs Syndrome
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356568
}}

{{PharmGKB
|RSID=rs1975197
|Name_s=
|Gene_s=PTPRD
|Feature=
|Evidence=PubMed ID:18660810
|Annotation=A study of 2,458 affected individuals and 4,749 controls from Germany, Austria, Czechia and Canada identified association of restless legs syndrome (RLS) with this variant in the 5' UTR of PTPRD gene.
|Drugs=
|Drug Classes=
|Diseases=Restless Legs Syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA162168966
}}

{{PMID Auto
|PMID=21264940
|Title=Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome
|OA=1
}}

{{PMID Auto GWAS
|PMID=21779176
|Trait=None
|Title=Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1.
|RiskAllele=A
|Pval=3E-10
|OR=1.2900
|ORtxt=[1.19-1.40]
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1975197
|overall_frequency_n=25
|overall_frequency_d=128
|overall_frequency=0.195312
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

[[Restless Legs Syndrome: Preliminary Research]]

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Affy500k}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}